Literature DB >> 30371656

Immunophenotyping of Orthotopic Homograft (Syngeneic) of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry.

Xiaoyu An1, Xuesong Ouyang2, Hui Zhang2, Tingting Li2, Yu-Yang Huang2, Zhiyuan Li2, Demin Zhou3, Qi-Xang Li4.   

Abstract

Homograft (syngeneic) tumors are the workhorse of today's immuno-oncology (I/O) preclinical research. The tumor microenvironment (TME), particularly its immune-components, is vital to the prognosis and prediction of treatment outcomes, especially those of immunotherapy. TME immune-components are composed of different subsets of tumor-infiltrating immune cells assessable by multi-color FACS. Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest malignances lacking good treatment options, thus an urgent and unmet medical need. One important reason for its non-responsiveness to various therapies (chemo-, targeted, I/O) has been its abundant TME, consisting of fibroblasts and leukocytes that protect tumor cells from these therapies. Orthotopically implanted PDAC is believed to more accurately recapture the TME of human pancreatic cancers than conventional subcutaneous (SC) models. Homograft tumors (KPC) are transplants of mouse spontaneous PDAC originating from genetically engineered KPC-mice (KrasG12D/+/P53-/-/Pdx1-Cre) (KPC-GEMM). The primary tumor tissue is cut into small fragments (~2 mm3) and transplanted subcutaneously (SC) to the syngeneic recipients (C57BL/6, 7-9 weeks old). The homografts were then surgically orthotopically transplanted onto the pancreas of new C57BL/6 mice, along with SC-implantation, which reached tumor volumes of 300-1,000 mm3 by 17 days. Only tumors of 400-600 mm3 were harvested per approved autopsy procedure and cleaned to remove the adjacent non-tumor tissues. They were dissociated per protocol using a tissue dissociator into single-cell suspensions, followed by staining with designated panels of fluorescently-labeled antibodies for various markers of different immune cells (lymphoid, myeloid and NK, DCs). The stained samples were analyzed using multi-color FACS to determine numbers of immune cells of different lineages, as well as their relative percentage within tumors. The immune profiles of orthotopic tumors were then compared to those of SC tumors. The preliminary data demonstrated significantly elevated infiltrating TILs/TAMs in tumors over the pancreas, and higher B-cell infiltration into orthotopic rather than SC tumors.

Entities:  

Mesh:

Year:  2018        PMID: 30371656      PMCID: PMC6235480          DOI: 10.3791/57460

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  21 in total

1.  PD-1 Blockade Expands Intratumoral Memory T Cells.

Authors:  Antoni Ribas; Daniel Sanghoon Shin; Jesse Zaretsky; Juliet Frederiksen; Andrew Cornish; Earl Avramis; Elizabeth Seja; Christine Kivork; Janet Siebert; Paula Kaplan-Lefko; Xiaoyan Wang; Bartosz Chmielowski; John A Glaspy; Paul C Tumeh; Thinle Chodon; Dana Pe'er; Begoña Comin-Anduix
Journal:  Cancer Immunol Res       Date:  2016-01-19       Impact factor: 11.151

2.  Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery.

Authors:  Suzanne I S Mosely; John E Prime; Richard C A Sainson; Jens-Oliver Koopmann; Dennis Y Q Wang; Danielle M Greenawalt; Miika J Ahdesmaki; Rebecca Leyland; Stefanie Mullins; Luciano Pacelli; Danielle Marcus; Judith Anderton; Amanda Watkins; Jane Coates Ulrichsen; Philip Brohawn; Brandon W Higgs; Matthew McCourt; Hazel Jones; James A Harper; Michelle Morrow; Viia Valge-Archer; Ross Stewart; Simon J Dovedi; Robert W Wilkinson
Journal:  Cancer Immunol Res       Date:  2016-12-06       Impact factor: 11.151

3.  Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.

Authors:  Gonzalo Gutiérrez-García; Teresa Cardesa-Salzmann; Fina Climent; Eva González-Barca; Santiago Mercadal; José L Mate; Juan M Sancho; Leonor Arenillas; Sergi Serrano; Lourdes Escoda; Salomé Martínez; Alexandra Valera; Antonio Martínez; Pedro Jares; Magdalena Pinyol; Adriana García-Herrera; Alejandra Martínez-Trillos; Eva Giné; Neus Villamor; Elías Campo; Luis Colomo; Armando López-Guillermo
Journal:  Blood       Date:  2011-03-25       Impact factor: 22.113

Review 4.  Experimental animal modeling for immuno-oncology.

Authors:  Qi-Xiang Li; Gerold Feuer; Xuesong Ouyang; Xiaoyu An
Journal:  Pharmacol Ther       Date:  2017-02-04       Impact factor: 12.310

Review 5.  Murine models to evaluate novel and conventional therapeutic strategies for cancer.

Authors:  James E Talmadge; Rakesh K Singh; Isaiah J Fidler; Avraham Raz
Journal:  Am J Pathol       Date:  2007-03       Impact factor: 4.307

6.  Genomic responses in mouse models greatly mimic human inflammatory diseases.

Authors:  Keizo Takao; Tsuyoshi Miyakawa
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

7.  Immune-cell lineage commitment: translation from mice to humans.

Authors:  Kimberly J Payne; Gay M Crooks
Journal:  Immunity       Date:  2007-06       Impact factor: 31.745

8.  PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells.

Authors:  Kathleen M Mahoney; Heather Sun; Xiaoyun Liao; Ping Hua; Marcella Callea; Edward A Greenfield; F Stephen Hodi; Arlene H Sharpe; Sabina Signoretti; Scott J Rodig; Gordon J Freeman
Journal:  Cancer Immunol Res       Date:  2015-11-06       Impact factor: 11.151

9.  An Immune Atlas of Clear Cell Renal Cell Carcinoma.

Authors:  Stéphane Chevrier; Jacob Harrison Levine; Vito Riccardo Tomaso Zanotelli; Karina Silina; Daniel Schulz; Marina Bacac; Carola Hermine Ries; Laurie Ailles; Michael Alexander Spencer Jewett; Holger Moch; Maries van den Broek; Christian Beisel; Michael Beda Stadler; Craig Gedye; Bernhard Reis; Dana Pe'er; Bernd Bodenmiller
Journal:  Cell       Date:  2017-05-04       Impact factor: 41.582

10.  Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.

Authors:  Hong Jiang; Samarth Hegde; Brett L Knolhoff; Yu Zhu; John M Herndon; Melissa A Meyer; Timothy M Nywening; William G Hawkins; Irina M Shapiro; David T Weaver; Jonathan A Pachter; Andrea Wang-Gillam; David G DeNardo
Journal:  Nat Med       Date:  2016-07-04       Impact factor: 53.440

View more
  1 in total

1.  Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment.

Authors:  Ying Jin; Xiaoyu An; Binchen Mao; Ruilin Sun; Rajendra Kumari; Xiaobo Chen; Yongli Shan; Mingfa Zang; Ling Xu; Jan Muntel; Kristina Beeler; Roland Bruderer; Lukas Reiter; Sheng Guo; Demin Zhou; Qi-Xiang Li; Xuesong Ouyang
Journal:  Sci Rep       Date:  2022-02-28       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.